Medicenna Therapeutics Corp operates as an immuno-oncology company. The Company develops and commercializes therapeutics for the treatment of the central nervous system and urological cancers.In November 2016, A2 Acquisition 1102209 BC, a subsidiary of A2 Acquisition entered into letter of intent to acquire Medicenna for undisclosed amount. The transaction was subject to receipt of the requisite shareholder approval of Medicenna, final approval of the TSX venture exchange and would close on or before February 28, 2017. In February 2017, A2 Acquisition signed a definitive agreement to acquire Medicenna. A total of 21,221,415 A2 consolidated shares would be issued in exchange for all the Medicenna shares (with a deemed price of CAD $2 (US $1.53) per A2 consolidated share). Upon completion, the former Medicenna shareholders would hold approximately 95.13% of the resulting issuer shares basis (without giving effect to the offering (as defined herein)) and the A2 shareholders would hold approximately 4.87% of